Drugs / Iniparib
Trials 20
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01455532 | Nov 2011 → May 2013 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01213381 | Sep 2010 → Feb 2013 | cancer of unknown primary site | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01161836 | Jul 2010 → Feb 2011 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT00422682 | Jan 2007 → Jan 2009 | neoplasm | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT00298675 | Mar 2006 → Jul 2010 | neoplasm | Sanofi | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00687765 | Jul 2008 → Jun 2015 | glioblastoma | Sanofi | Completed | No outcome recorded |
| Phase 210 trials · 1 met primary · 3 missed | ||||||
| Phase 2 | NCT01204125 | Sep 2010 → Oct 2012 | female breast carcinoma | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01173497 | Jul 2010 → Oct 2012 | Her2-receptor negative breast cancer, estrogen-receptor negative breast cancer, metastatic malignant neoplasm in the brain, progesterone-receptor negative breast cancer | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01086254 | May 2010 → Dec 2011 | non-small cell lung carcinoma | Sanofi | Completed | Missed primary |
| Phase 2 | NCT01045304 | Feb 2010 → Mar 2011 | breast carcinoma | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01033292 | Dec 2009 → Dec 2012 | ovarian cancer | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01033123 | Dec 2009 → Feb 2012 | ovarian cancer | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00813956 | Dec 2008 → Oct 2012 | triple-negative breast carcinoma | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00677079 | Jun → Dec 2008 | malignant epithelial tumor of ovary, primary peritoneal carcinoma | Sanofi | Completed | Missed primary |
| Phase 2 | NCT00687687 | May 2008 → Mar 2010 | uterine carcinosarcoma | Sanofi | Completed | Missed primary |
| Phase 2 | NCT00540358 | Oct 2007 → Nov 2009 | breast cancer | Sanofi | Completed | Met primary |
| Phase 33 trials | ||||||
| Phase 3 | NCT01593228 | May 2012 → Sep 2016 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01082549 | Mar 2010 → Apr 2013 | non-small cell squamous lung carcinoma | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00938652 | Jul 2009 → Jan 2011 | breast cancer | Sanofi | Completed | Mixed |
| Phase not stated1 trial | ||||||
| — | NCT01130259 | — | breast cancer | Sanofi | No longer available | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iniparib | “Iniparib (BSI-201), a novel anticancer agent thought to have poly(ADP-ribose) polymerase (PARP) inhibitory activity and synergy with both gemcitabine and carboplatin (GC) was...” PMID 36718018 ↗ Mar 202316“Iniparib (BSI-201), a novel anticancer agent thought to have poly(ADP-ribose) polymerase (PARP) inhibitory activity and synergy with both gemcitabine and carboplatin (GC) was...” PMID 36718018 ↗ Mar 2023 “BSI-201 (iniparib)” NCT00298675 ↗ |
| Known as | BSI-201 | “Iniparib (BSI-201), a novel anticancer agent thought to have poly(ADP-ribose) polymerase (PARP) inhibitory activity and synergy with both gemcitabine and carboplatin (GC) was...” PMID 36718018 ↗ Mar 202310“A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis” NCT01173497 ↗ “Iniparib (SAR240550 - BSI-201)” NCT01213381 ↗ “Iniparib (SAR2405550 -BSI-201)” NCT01204125 ↗ “Iniparib (SAR240550/BSI-201)” NCT01593228 ↗ “Iniparib (BSI201/SAR240550)” NCT01455532 ↗ |
| Known as | SAR240550 | “Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)” NCT01082549 ↗ |
| Known as | SAR240550-BSI-201 | “Iniparib (SAR240550-BSI-201)” NCT01455532 ↗ |
| Known as | SAR2405550 | “Iniparib (SAR2405550 -BSI-201)” NCT01204125 ↗ |
| Action | Inhibit | “Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201” NCT00687765 ↗ |
| Modality | Small molecule | “with or without iniparib, a small molecule” PMID 21208101 ↗ Jan 2011 |
| Route | Intravenous | “BSI-201 administered intravenously (IV)” NCT00298675 ↗ |
| Target | PARP1 | “Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201” NCT00687765 ↗ |